A listing for this trial in a federal database indicates the study is still recruiting and has not yet been terminated
This is where retatrutide pulls ahead in a way that tirzepatide simply cannot match at any dose, and the data is striking enough to change how researchers think about these compounds
OMAD: One meal a day extreme, but some use it for simplicity
Unlike California and Pennsylvania, which provide broad coverage for all obesity-indicated GLP-1s, Kentuckys Medicaid program covers only Wegovy for weight management alongside Type 2 diabetes-indicated medications
Market growth is supported by several factors including an aging global population, increasing prevalence of chronic diseases, and growing acceptance of biological therapies
When interpreted with your clinical biomarkersfasting glucose, HbA1c, weight, and metabolic comorbiditiesgenetic insights can help your provider tailor dosing, titration speed, and duration expectations, potentially optimizing cost-effectiveness over time
.jpg)
